Abstract

Neurotrophins signal via Trk tyrosine kinase receptors. Nerve growth factor (NGF) is the cognate ligand for TrkA, the brain-derived neurotrophic factor for TrkB, and NT-3 for TrkC. NT-3 also binds TrkA as a lower affinity heterologous ligand. Because neurotrophin-3 (NT-3) interactions with TrkA are biologically relevant, we aimed to define the TrkA "hot spot" functional docking sites of NT-3. The Trk extracellular domain consists of two cysteine-rich subdomains (D1 and D3), flanking a leucine-rich subdomain (D2), and two immunoglobulin-like subdomains IgC1(D4) and IgC2(D5). Previously, the D5 subdomain was defined as the primary ligand-binding site of neurotrophins for their cognate receptors (e.g. NGF binds and activates through TRKA-D5 hot spots). Here binding studies with truncated and chimeric extracellular subdomains show that TRKA-D5 also includes an NT-3 docking and activation hot spot (site 1), and competition studies show that the NGF and NT-3 hot spots on TRKA-D5 are distinct but partially overlapping. In addition, ligand binding studies provide evidence for an NT-3-binding/allosteric site on TRKA-D4 (site 2). NT-3 docking on sites 1 and/or 2 partially blocks NGF binding. Functional survival studies showed that sites 1 and 2 regulate TrkA activation. NT-3 docking on both sites 1 and 2 affords full agonism, which can be additive with NGF activation of Trk. However, NT-3 docking solely on site 1 is partially agonistic but noncompetitively antagonizes NGF binding and activation of Trk. This study demonstrates that Trk signaling is more complex than previously thought because it involves several receptor subdomains and hot spots.

Highlights

  • Trk total phosphorylation, phospho-Tyr-490, and p-Akt correlate well with the survival response of TrkA WT or 4.1 TrkA/B-expressing cells to each ligand or ligand combination

  • TrkA wild type it is additive with NGF

  • Quantification showed that 2 nM NGF plus 500 nM NT-3 affords 54% Ϯ 2 of 4.1 TrkA/B phosphorylation compared versus 2 nM NGF

Read more

Summary

Introduction

Trk total phosphorylation, phospho-Tyr-490, and p-Akt correlate well with the survival response of TrkA WT or 4.1 TrkA/B-expressing cells to each ligand or ligand combination. Similar results were obtained when phospholipase C␥ activation was studied (data not shown). These results confirm the notion that NT-3 acting in 4.1 TrkA/B chimera via TRKA-D5 is a pure partial agonist that can antagonize NGF. NT-3 acting in wild type TrkA via D5 and other subdomains (likely D4) can be a full agonist that can be additive with NGF functio

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call